A phase I trial and a preclinical study found viral immunotherapy triggered T cell responses in glioblastoma. The clinical study enrolled 41 patients; the mouse study showed prolonged survival and immunologic memory.
Two studies identify protein recycling dysfunction and transcription factors ZSCAN20/JDP2 as drivers of T-cell exhaustion, with E3 ligases and gene deactivation offering reversal pathways. A third study finds TCF1 insufficient to revert terminally exhausted T cells.
Researchers identify DPY30 as an epigenetic target to sensitize pancreatic tumors to immunotherapy. UC San Diego researchers redirect CMV immunity against pancreatic cancer in preclinical models. A Fred Hutch researcher receives ACS grant to study immunotherapy resistance in melanoma.
VYLOY (zolbetuximab-clzb) remains the only approved CLDN18.2-targeted therapy for first-line HER2-negative gastric or gastroesophageal junction adenocarcinoma with CLDN18.2-positive tumors. The pipeline is focused on next-generation antibodies, ADCs, CAR-T, NK-cell and bispecific approaches aiming to build on zolbetuximab benchmark data.
A novel therapeutic vaccine using structural nanomedicine principles has shown promising results against HPV-driven cancers in preclinical models. The spherical nucleic acid vaccine design significantly slowed tumor growth and extended survival by generating potent T-cell responses. Unlike preventive HPV vaccines, this approach is designed to treat established cancers caused by the virus.
Moffitt Cancer Center researchers published findings on plant-based diets and cancer risk, identified spatial tumor-immune patterns predicting immunotherapy response, and hosted a summit on engineering-driven cancer research innovations.
A prospective multicenter study found that baseline gut microbiome diversity selectively stratifies benefit from dual checkpoint blockade in advanced NSCLC, with high diversity associated with prolonged survival on immunotherapy alone while low diversity patients benefit from added chemotherapy.
A first-in-human trial shows individualized neoantigen mRNA vaccines generated multi-year T cell responses in early-stage TNBC patients, with 82.9% of targeted mutations eliciting measurable immune activation not detectable before vaccination.
Moderna and Merck are recruiting patients for a Phase 2 trial testing V940, an mRNA-based cancer vaccine, combined with Keytruda and chemotherapy as first-line treatment for metastatic squamous non-small cell lung cancer.
AIM ImmunoTech outlined key milestones for its Phase 2 DURIPANC trial evaluating Ampligen combined with durvalumab in metastatic pancreatic cancer, with primary endpoint evaluation expected in December 2026.
